Vinpocetine-OBL, tablets 10 mg 30 pcs

Vinpocetine is a drug that improves blood circulation and metabolism of the brain, has vasodilator, antihypoxic, anti-aggregation action.

Inhibits phosphodiesterase and increases cyclic adenosine monophosphate in cells, which leads to a decrease of calcium in the cytoplasm of smooth muscle cells and relaxation of myofibrils.

Dilates brain vessels, increases blood flow, mainly in ischemic areas, improves the supply of oxygen to the brain.

Promotes glucose utilization and increases catecholamine levels in the central nervous system and stimulates the metabolism of noradrenaline and serotonin in brain tissue.

Decreases platelet aggregation and blood viscosity, increases the deformability of red blood cells and normalizes venous outflow against reduced resistance of cerebral vessels.

The systemic arterial pressure slightly decreases.

In old age and old age, the sensitivity of cerebral vessels to the relaxing action of Vinpocetine increases due to sensitization of the adenylate cyclic adenosine monophosphate system with aging.

Indications

Acute and chronic insufficiency of cerebral circulation.

Discirculatory encephalopathy, accompanied by memory impairment, dizziness, headache.

Post-traumatic encephalopathy.

Vascular diseases of the retina and vasculature.

Hearing impairment of vascular or toxic genesis, Meniere’s disease, vertigo of labyrinthine origin.

Vascular dystonia in menopausal syndrome.

Active ingredient

Composition

The active ingredient – Vinpocetine 10 mg;

excipients – potato starch,

milk sugar (lactose),

microcrystalline cellulose,

magnesium stearate,

talc,

colloidal silicon dioxide (aerosil).

How to take, the dosage

Ingestion, after meals, 3 times a day.

The initial daily dose is 15 mg.

The maximum daily dose is 30 mg.

The duration of the course of treatment is up to 3 months.

In case of kidney or liver disease, the drug is prescribed in the usual dose.

Interaction

When used concomitantly with warfarin, a slight decrease in the anticoagulant effect of warfarin has been reported.

Concomitant parenteral use of vinpocetine and heparin may increase the risk of bleeding.

Special Instructions

The presence of prolonged QT interval syndrome and taking drugs that cause prolongation of the QT interval require periodic ECG monitoring.

In case of lactose intolerance, note that one tablet contains about 225 mg of lactose.

Contraindications

Side effects

Cardiovascular system: ECG changes (ST depression, prolongation of the QT interval), tachycardia, extrasystole, blood pressure lability, tidal sensations.

Digestive system disorders: dry mouth, nausea, heartburn.

From the central nervous system: sleep disorders (insomnia or increased sleepiness), dizziness, headache.

Others: allergic reactions, general weakness, increased sweating.

Overdose

There have been no reported cases of overdose of the drug Vinpocetine.

Treatment: gastric lavage, administration of activated charcoal; if necessary symptomatic therapy is carried out.

Similarities